

Urological Cancer Drugs-Asia Pacific Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/UA044D42B56MEN.html>

Date: April 2018

Pages: 154

Price: US\$ 3,480.00 (Single User License)

ID: UA044D42B56MEN

Abstracts

Report Summary

Urological Cancer Drugs-Asia Pacific Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Urological Cancer Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Asia Pacific and Regional Market Size of Urological Cancer Drugs 2013-2017, and development forecast 2018-2023

Main market players of Urological Cancer Drugs in Asia Pacific, with company and product introduction, position in the Urological Cancer Drugs market

Market status and development trend of Urological Cancer Drugs by types and applications

Cost and profit status of Urological Cancer Drugs, and marketing status

Market growth drivers and challenges

The report segments the Asia Pacific Urological Cancer Drugs market as:

Asia Pacific Urological Cancer Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

China

Japan

Korea

India

Southeast Asia

Australia

Asia Pacific Urological Cancer Drugs Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Xofigo (Radium Ra 223 Dichloride)

Jevtana (Cabazitaxel)

Inlyta (Axitinib)

Votrient (Pazopanib Hydrochloride)

Sutent (Sunitinib Malate)

Zytiga (Abiraterone Acetate)

Xtandi (Enzalutamide)

Opdivo (Nivolumab)

Provenge (Sipuleucel-T)

Asia Pacific Urological Cancer Drugs Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and
Market Analysis)

Prostate Cancer

Bladder Cancer

Kidney Cancer

Testicular Cancer

Asia Pacific Urological Cancer Drugs Market: Players Segment Analysis (Company and
Product introduction, Urological Cancer Drugs Sales Volume, Revenue, Price and
Gross Margin):

Novartis

Pfizer

Johnson & Johnson

AstraZeneca

Astellas

Bristol-Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline

Indevus Pharmaceuticals Inc

Ipsen

Roche Healthcare

Sanofi S.A.
Tolmar Inc

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF UROLOGICAL CANCER DRUGS

- 1.1 Definition of Urological Cancer Drugs in This Report
- 1.2 Commercial Types of Urological Cancer Drugs
 - 1.2.1 Xofigo (Radium Ra 223 Dichloride)
 - 1.2.2 Jevtana (Cabazitaxel)
 - 1.2.3 Inlyta (Axitinib)
 - 1.2.4 Votrient (Pazopanib Hydrochloride)
 - 1.2.5 Sutent (Sunitinib Malate)
 - 1.2.6 Zytiga (Abiraterone Acetate)
 - 1.2.7 Xtandi (Enzalutamide)
 - 1.2.8 Opdivo (Nivolumab)
 - 1.2.9 Provenge (Sipuleucel-T)
- 1.3 Downstream Application of Urological Cancer Drugs
 - 1.3.1 Prostate Cancer
 - 1.3.2 Bladder Cancer
 - 1.3.3 Kidney Cancer
 - 1.3.4 Testicular Cancer
- 1.4 Development History of Urological Cancer Drugs
- 1.5 Market Status and Trend of Urological Cancer Drugs 2013-2023
 - 1.5.1 Asia Pacific Urological Cancer Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Urological Cancer Drugs Market Status and Trend 2013-2023

CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Urological Cancer Drugs in Asia Pacific 2013-2017
- 2.2 Consumption Market of Urological Cancer Drugs in Asia Pacific by Regions
 - 2.2.1 Consumption Volume of Urological Cancer Drugs in Asia Pacific by Regions
 - 2.2.2 Revenue of Urological Cancer Drugs in Asia Pacific by Regions
- 2.3 Market Analysis of Urological Cancer Drugs in Asia Pacific by Regions
 - 2.3.1 Market Analysis of Urological Cancer Drugs in China 2013-2017
 - 2.3.2 Market Analysis of Urological Cancer Drugs in Japan 2013-2017
 - 2.3.3 Market Analysis of Urological Cancer Drugs in Korea 2013-2017
 - 2.3.4 Market Analysis of Urological Cancer Drugs in India 2013-2017
 - 2.3.5 Market Analysis of Urological Cancer Drugs in Southeast Asia 2013-2017
 - 2.3.6 Market Analysis of Urological Cancer Drugs in Australia 2013-2017
- 2.4 Market Development Forecast of Urological Cancer Drugs in Asia Pacific 2018-2023

2.4.1 Market Development Forecast of Urological Cancer Drugs in Asia Pacific
2018-2023

2.4.2 Market Development Forecast of Urological Cancer Drugs by Regions
2018-2023

CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES

3.1 Whole Asia Pacific Market Status by Types

3.1.1 Consumption Volume of Urological Cancer Drugs in Asia Pacific by Types

3.1.2 Revenue of Urological Cancer Drugs in Asia Pacific by Types

3.2 Asia Pacific Market Status by Types in Major Countries

3.2.1 Market Status by Types in China

3.2.2 Market Status by Types in Japan

3.2.3 Market Status by Types in Korea

3.2.4 Market Status by Types in India

3.2.5 Market Status by Types in Southeast Asia

3.2.6 Market Status by Types in Australia

3.3 Market Forecast of Urological Cancer Drugs in Asia Pacific by Types

CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Urological Cancer Drugs in Asia Pacific by Downstream Industry

4.2 Demand Volume of Urological Cancer Drugs by Downstream Industry in Major
Countries

4.2.1 Demand Volume of Urological Cancer Drugs by Downstream Industry in China

4.2.2 Demand Volume of Urological Cancer Drugs by Downstream Industry in Japan

4.2.3 Demand Volume of Urological Cancer Drugs by Downstream Industry in Korea

4.2.4 Demand Volume of Urological Cancer Drugs by Downstream Industry in India

4.2.5 Demand Volume of Urological Cancer Drugs by Downstream Industry in
Southeast Asia

4.2.6 Demand Volume of Urological Cancer Drugs by Downstream Industry in
Australia

4.3 Market Forecast of Urological Cancer Drugs in Asia Pacific by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF UROLOGICAL CANCER DRUGS

5.1 Asia Pacific Economy Situation and Trend Overview

5.2 Urological Cancer Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 UROLOGICAL CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC

6.1 Sales Volume of Urological Cancer Drugs in Asia Pacific by Major Players

6.2 Revenue of Urological Cancer Drugs in Asia Pacific by Major Players

6.3 Basic Information of Urological Cancer Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Urological Cancer Drugs Major Players

6.3.2 Employees and Revenue Level of Urological Cancer Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 UROLOGICAL CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Novartis

7.1.1 Company profile

7.1.2 Representative Urological Cancer Drugs Product

7.1.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis

7.2 Pfizer

7.2.1 Company profile

7.2.2 Representative Urological Cancer Drugs Product

7.2.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Pfizer

7.3 Johnson & Johnson

7.3.1 Company profile

7.3.2 Representative Urological Cancer Drugs Product

7.3.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson

7.4 AstraZeneca

7.4.1 Company profile

7.4.2 Representative Urological Cancer Drugs Product

7.4.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca

7.5 Astellas

7.5.1 Company profile

- 7.5.2 Representative Urological Cancer Drugs Product
- 7.5.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas
- 7.6 Bristol-Myers Squibb
 - 7.6.1 Company profile
 - 7.6.2 Representative Urological Cancer Drugs Product
 - 7.6.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
- 7.7 Abbott Laboratories
 - 7.7.1 Company profile
 - 7.7.2 Representative Urological Cancer Drugs Product
 - 7.7.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
- 7.8 Celgene Corporation
 - 7.8.1 Company profile
 - 7.8.2 Representative Urological Cancer Drugs Product
 - 7.8.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Celgene Corporation
- 7.9 Dendreon Corporation
 - 7.9.1 Company profile
 - 7.9.2 Representative Urological Cancer Drugs Product
 - 7.9.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
- 7.10 Ferring Pharmaceuticals
 - 7.10.1 Company profile
 - 7.10.2 Representative Urological Cancer Drugs Product
 - 7.10.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals
- 7.11 GlaxoSmithKline
 - 7.11.1 Company profile
 - 7.11.2 Representative Urological Cancer Drugs Product
 - 7.11.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
- 7.12 Indevus Pharmaceuticals Inc
 - 7.12.1 Company profile
 - 7.12.2 Representative Urological Cancer Drugs Product
 - 7.12.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Indevus Pharmaceuticals Inc
- 7.13 Ipsen
 - 7.13.1 Company profile

- 7.13.2 Representative Urological Cancer Drugs Product
- 7.13.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ipsen
- 7.14 Roche Healthcare
 - 7.14.1 Company profile
 - 7.14.2 Representative Urological Cancer Drugs Product
 - 7.14.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Roche Healthcare
- 7.15 Sanofi S.A.
 - 7.15.1 Company profile
 - 7.15.2 Representative Urological Cancer Drugs Product
 - 7.15.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.
- 7.16 Tolmar Inc

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF UROLOGICAL CANCER DRUGS

- 8.1 Industry Chain of Urological Cancer Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF UROLOGICAL CANCER DRUGS

- 9.1 Cost Structure Analysis of Urological Cancer Drugs
- 9.2 Raw Materials Cost Analysis of Urological Cancer Drugs
- 9.3 Labor Cost Analysis of Urological Cancer Drugs
- 9.4 Manufacturing Expenses Analysis of Urological Cancer Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF UROLOGICAL CANCER DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy

- 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Urological Cancer Drugs-Asia Pacific Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/UA044D42B56MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UA044D42B56MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970